Text -2,561 (including abstract) Abstract 1 Background: Immune-modulating drugs have recently been introduced to the second 2 line setting of advanced bladder cancer. Pembrolizumab increases overall survival and 3 is associated with less toxicity compared to chemotherapy in this setting based on the 4 Keynote 045 study. The high cost of immunotherapy necessitates an assessment of its 5 value by considering both efficacy and cost. 6
1 CAD for Canada [US$16,000-80,000] and 40,000-75,000 AUD for Australia 25 [US$32,000-60,000]. 26
Conclusions: Cost-effectiveness and WTP thresholds vary between countries. 27
Compared to the other countries examined, U.S. drug prices were found to be highest, 28 leading to the highest ICER. With standard willingness-to-pay thresholds, 29 pembrolizumab may be considered cost-effective in the U.S., but not in the other 30 countries examined. 31 32 Patient summary: This article assessed the cost-effectiveness of pembrolizumab for 33 treatment of patients with metastatic bladder cancer who have previously failed one 34 treatment regimen. It would cost $122,557 in the U.S., $91,995 in the U.K., $90,099 35 in Canada and $99,966 in Australia to gain one quality-adjusted life-year with 36 pembrolizumab versus chemotherapy in these patients, which may be considered cost-37
Introduction 42
Metastatic bladder cancer is a lethal disease, with only 5% of patients surviving 5 43 years 1 . Platinum-based chemotherapy is the standard of care for patients with 44 advanced disease. Unfortunately, after disease progression; second-line chemotherapy 45 yields a response rate of only around 10% with considerable toxicities 2 . Recently, 46 immunotherapy has shown activity in advanced bladder cancer, with 5 checkpoint 47 inhibitors gaining FDA approval for second-line therapy (pembrolizumab, nivolumab, 48 atezolizumab, avelumab, durvalumab) 3 . Pembrolizumab is the only FDA approved 49 checkpoint inhibitor that has so far shown an overall survival benefit in this 50 indication, based on the Keynote 045 study 4 . This pivotal phase III study 51 demonstrated a 2.9 month improved median overall survival with pembrolizumab 52 compared to chemotherapy (10.3 vs. 7.4 months, hazard ratio 0.73). Responding 53 patients on pembrolizumab tended to have longer responses, and the flattening of the 54 survival curve for pembrolizumab hints towards durable survival in some patients. 55
The toxicity profile was also improved, with patients typically suffering from asthenia 56 and infrequently from immune-mediated side effects. 57
58
The growing cost of cancer care in the era of immunotherapy is of great concern for 59 public and private payers and for individual patients around the world. This concern 60 triggered both the American 5 and European 6 oncology societies to develop value 61 frameworks for cancer drugs. A standard, well validated method to examine a drug's 62 value is by a cost-effectiveness analysis (CEA), which considers both cost and 63 efficacy in its specific indication. As drug prices and willingness to pay thresholds 64 vary around the world 7 , the CEA estimates the value in a specific setting and is not 65 exchangeable between countries. The objective of this study was to estimate the cost-66 effectiveness of pembrolizumab for second-line treatment of advanced bladder cancer 67 from the perspective of payers in multiple countries, specifically the U.S., U.K., 68 Canada and Australia. 69
70
Methods 71
Model Structure 72
The Markov model involved an initial treatment decision with either pembrolizumab 73 or chemotherapy ( Fig. 1 The probability for transition from a progression-free state to a post-progression state 88 was derived from the Progression-Free Survival (PFS) curves in the Keynote 045 trial. 89
The probability for transition from any state to the death state was derived from the 90 overall survival (OS) curves in the Keynote 045 trial. For the pembrolizumab and 91 chemotherapy arms we used Plot Digitizer software (version 2.1; http://plotdigitizer. 92 sourceforge.net) to extract the data points from each PFS and OS plot from the 93 Keynote 045 trial, and these data points were then used to fit parametric models. We included in the model grade 3 to 4 AEs that had significantly different rates 121 between the arms of the Keynote 045 trial 4 , which were anemia, neutropenia and 122 febrile neutropenia. The treatment of AEs was estimated based on clinical experience, 123 similar to a previous study 10 . We assumed that an episode of febrile neutropenia 124 would be managed with a 5-day hospitalization. We assumed that grade 3/4 anemia 125 would be managed with one outpatient visit and transfusion of two units of red blood 126 cells (RBC). All costs and health outcomes were discounted by 3% annually for the 127 U.S., U.K. and Australia 11 , and 1.5% for Canada 12 . We adjusted all cost estimates for 128 each individual country, similar to a previous study 11 . We used prices that, to the best 129 of our knowledge, account for non-confidential discounts and rebates. However we 130 were unable to account for any country specific confidential discounts. Details of drug 131 costs are available in Table 1 and in the supplemental material. 132 133
Sensitivity analysis 134
A series of sensitivity analyses was performed to evaluate the robustness of the model 135 and to address the uncertainty in the estimation of variables. Utilities incorporated a 136 ±10% range as described above. Drug costs varied within ±20% of their baseline 137 values to account for alternative public and private payers that may pay less or more 138 respectively, as in a similar study 13 . In univariate sensitivity analyses, we varied the 139 value of one parameter at a time over its defined range and examined the effect on the 140 ICER. In probabilistic sensitivity analyses (PSA), we ran the model 10,000 times, Pembrolizumab generated a gain of 0.36 QALYs over chemotherapy for the U.S., 162 U.K. and Australia, and 0.37 QALY for Canada (due to different discounting rates). 163
In the U.S., U.K., Canada, and Australia, in comparison with the base case results, the 164 ICER, meaning the additional cost of pembrolizumab versus chemotherapy was 165 $122,557, $91,995, $90,099, and $99,966 per QALY gained, respectively. Table 2  166 demonstrates these base case results. It is important to note that the WTP threshold varies between different countries and 202 is a matter of much debate, as its precise figure is elusive. In the U.S. the WTP 203 threshold is considered to be $50,000-150,000 per QALY 17 , although many cancer 204 drugs are in use despite an ICER above this threshold 13 . In the U.K. the WTP 205 threshold is considered to be 20,000-30,000 pounds [25,000-38,000 US $] and 50,000 whether pembrolizumab is cost-effective are presented in Table 2 . In August 2017 the 218 U.K. National Institute for Health and Care Excellence (NICE) announced that 219 pembrolizumab is not cost-effective for metastatic bladder cancer due to its high cost, 220 despite meeting the end-of-life criteria 22 . 221 Our analysis was limited by data availability and our assumptions. We assumed that 222 survival benefits, utilities, and AE incidence and management were standard between 223 countries. We used American data for mean BSA, which might differ slightly between 224 countries. We did not include taxes on drug costs for any country, as tax rates and 225 criteria are different between countries. We did not account for crossover, and in the 226 trial 12.9% of patients in the chemotherapy arm received subsequent immunotherapy. 227
This may potentially underestimate the survival benefit with pembrolizumab. In the 228 sensitivity analyses we used a range for certain values to account for possible 229 inaccuracies, as described above. Such inaccuracies may include differences between 230 the trial participants and real world patients, as it is likely that in the real world 231 pembrolizumab will be given to frailer patients due to its low toxicity. Also as there 232 are no third line approved therapies, at first radiographic progression many real world 233 patients are likely to continue therapy until the next evaluation to account for the 234 possibility of pseudo-progression. Both differences may cause a lower utility and an 235 increased cost of pembrolizumab, thus increasing the ICER. As vinflunine is not FDA 236 approved and is not regularly used in clinical practice in any of the countries 237 examined we decided not to incorporate it in the analysis. When incorporating 238 vinflunine costs into the model the U.K. ICER changes from $91,995 to $81,850, and 239 is still considered not to be cost-effective. To account for the possibility of no survival 240 benefit with second-line chemotherapy we added a structural sensitivity analysis of 241 pembrolizumab versus placebo (eTable 3 in supplement). The modeling of AEs 242 included only significantly different incidence rates of grade 3 to 4 toxicity between 243 treatments, thus immune-related AEs were not included due to few events. As the 244 recent FDA approval 3 Nevertheless, due to a higher WTP threshold, pembrolizumab may potentially be 261 considered cost-effective in the U.S., but not in the other countries. 262 Tables and Figures  263   Table 1 -Treatment 
Costs
We adjusted all cost estimates for each individual country. All costs were sourced between 2013 and 2017 and were converted from local currency to U.S. dollars using the exchange rates on September 1, 2017: one U.S. dollar was equivalent to 0.77 U.K. pounds, 1.25 Australian dollars and 1.24 Canadian dollars 1 . We did not include sales tax.
U.S. Costs
For US prices we used the 2016 average sales price by the Centers for Medicare and Medicaid services plus 4.2% to simulate Medicare reimbursement. Administration costs and adverse event costs were calculated according to the Medicare physician fee schedule for 2016. The costs for grade 3/4 AEs were based on diagnosis related group (DRG) codes. The fees for outpatient physician visits were based on Current Procedure Terminology codes 2,3 .
U.K. Costs
To estimate the unit price for generic drugs, we used the U.K. Department of Health Commercial Medicines Unit electronic Medicines Information Tool 4 . To estimate the unit price for patented drugs, we used the U.K. 
Canada Costs
To estimate the unit price of drugs, we used the Ontario Drug Benefit Formulary 7 and Sunnybrook Pharmacy Stores Department (Kelvin Chan, personal communication). The costs of chemotherapy supervision were estimated by duration of nursing and pharmacy time as estimated by Cancer Care Ontario 8 and multiplied by their estimated hourly wage 9 . The outpatient physician visits cost was obtained from the Ontario Schedule of Benefits 10 . In Ontario, Canada, there is a differential pricing structure for clinic visits based on the number of prior visits. In order to make appropriate comparisons between countries and not to adjust the overall design of the model, we estimated the price of a single clinic visit as the mean of the first five clinic visits. Although any difference in actual prices would likely have only a tiny impact on the model results, these differences would be accounted for in the subsequent sensitivity analyses.
Australia Costs
Drug prices were collected from the 2017 Pharmaceutical Benefits Scheme prices 11 . This is a federally funded pharmaceutical scheme with nationwide coverage. Administration costs and physician visits were based on the 2017 Medicare Benefits Schedule prices for outpatient health services 12 . Blood products were based on the 2017 National Blood Authority Australia prices 13 .
